// App-Quantinova.ai

: Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Researchers

Presenter

  • Franck Morschhauser

Principal Investigators

  • John Radford

  • Loic Ysebaert

  • Stephen E Spurgeon

  • Ebenezer A Kio

  • Gilles Salles

  • Xi Huang

  • Siddhartha Mitra

  • Simon Rule

  • Martin J.S. Dyer

Medical Centers

  • Manchester Academic Health Science Centre, University of Manchester, Manchester University NHS Foundation Trust, Manchester, United Kingdom.

  • IUC Toulouse-Oncopole, Toulouse University Hospitals, Toulouse, France

  • Knight Cancer Institute, Oregon Health and Science University, Portland, OR

  • Goshen Center for Cancer Care, Goshen, IN

  • Hospices Civils de Lyon and Universite de Lyon, Pierre-Benite, France

  • Gilead Sciences, Inc., Foster City, CA

  • Department of Haematology, Plymouth University Medical School, Plymouth, United Kingdom

  • The Ernest and Helen Scott Haematological Research Institute, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom

Locations

  • France

  • United Kingdom

  • United States

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Waldenstrom’s macroglobulinemia

  • Diffuse large B-cell lymphoma

  • Mucosa-associated lymphoid tissue lymphoma

  • Mantle cell lymphoma

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Tirabrutinib

  • Idelalisib

Outcome

  • N/A

Study Design

  • Fixed Dose

  • Expansion Study

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT02457598

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved